JP2016523560A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016523560A5 JP2016523560A5 JP2016525414A JP2016525414A JP2016523560A5 JP 2016523560 A5 JP2016523560 A5 JP 2016523560A5 JP 2016525414 A JP2016525414 A JP 2016525414A JP 2016525414 A JP2016525414 A JP 2016525414A JP 2016523560 A5 JP2016523560 A5 JP 2016523560A5
- Authority
- JP
- Japan
- Prior art keywords
- rna
- cell
- target nucleic
- nucleic acid
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 47
- 210000004027 cell Anatomy 0.000 claims description 44
- 108091033409 CRISPR Proteins 0.000 claims description 31
- 101710163270 Nuclease Proteins 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 26
- 230000002950 deficient Effects 0.000 claims description 22
- 108090000623 proteins and genes Proteins 0.000 claims description 21
- 102000004169 proteins and genes Human genes 0.000 claims description 19
- 108020005004 Guide RNA Proteins 0.000 claims description 12
- 230000000295 complement effect Effects 0.000 claims description 12
- 108020004414 DNA Proteins 0.000 claims description 6
- 108010008532 Deoxyribonuclease I Proteins 0.000 claims description 5
- 102000007260 Deoxyribonuclease I Human genes 0.000 claims description 5
- 230000027455 binding Effects 0.000 claims description 5
- 230000004927 fusion Effects 0.000 claims description 5
- 238000013518 transcription Methods 0.000 claims description 5
- 230000035897 transcription Effects 0.000 claims description 5
- 238000010354 CRISPR gene editing Methods 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims 61
- 102000039446 nucleic acids Human genes 0.000 claims 61
- 150000007523 nucleic acids Chemical class 0.000 claims 60
- 102000052510 DNA-Binding Proteins Human genes 0.000 claims 21
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 claims 18
- 101710096438 DNA-binding protein Proteins 0.000 claims 17
- 101000709520 Chlamydia trachomatis serovar L2 (strain 434/Bu / ATCC VR-902B) Atypical response regulator protein ChxR Proteins 0.000 claims 11
- 239000002773 nucleotide Substances 0.000 claims 6
- 125000003729 nucleotide group Chemical group 0.000 claims 6
- 230000002411 adverse Effects 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 4
- 108700020911 DNA-Binding Proteins Proteins 0.000 claims 4
- 230000004570 RNA-binding Effects 0.000 claims 4
- 108020005196 Mitochondrial DNA Proteins 0.000 claims 2
- 108020005202 Viral DNA Proteins 0.000 claims 2
- 210000004102 animal cell Anatomy 0.000 claims 2
- 230000008045 co-localization Effects 0.000 claims 2
- 230000001276 controlling effect Effects 0.000 claims 2
- 210000003527 eukaryotic cell Anatomy 0.000 claims 2
- 108091006106 transcriptional activators Proteins 0.000 claims 2
- 210000005253 yeast cell Anatomy 0.000 claims 2
- 230000001105 regulatory effect Effects 0.000 claims 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 10
- 238000010586 diagram Methods 0.000 description 9
- 125000006850 spacer group Chemical group 0.000 description 7
- 238000003556 assay Methods 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- 241000589602 Francisella tularensis Species 0.000 description 4
- 229940118764 francisella tularensis Drugs 0.000 description 4
- 241000032681 Gluconacetobacter Species 0.000 description 3
- 241000194019 Streptococcus mutans Species 0.000 description 3
- 108091027544 Subgenomic mRNA Proteins 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 238000002744 homologous recombination Methods 0.000 description 3
- 230000006801 homologous recombination Effects 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 241000589875 Campylobacter jejuni Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 241000193985 Streptococcus agalactiae Species 0.000 description 2
- 241000193996 Streptococcus pyogenes Species 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000005782 double-strand break Effects 0.000 description 2
- 238000010362 genome editing Methods 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000006780 non-homologous end joining Effects 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 241001041760 Acidothermus cellulolyticus 11B Species 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 241000186063 Arthrobacter Species 0.000 description 1
- 241000589941 Azospirillum Species 0.000 description 1
- 241000193755 Bacillus cereus Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000606124 Bacteroides fragilis Species 0.000 description 1
- 241000586987 Bifidobacterium dentium Bd1 Species 0.000 description 1
- 241001209261 Bifidobacterium longum DJO10A Species 0.000 description 1
- 241001453247 Campylobacter jejuni subsp. doylei Species 0.000 description 1
- 241000941427 Campylobacter lari RM2100 Species 0.000 description 1
- 241001034636 Capnocytophaga ochracea DSM 7271 Species 0.000 description 1
- 241000193155 Clostridium botulinum Species 0.000 description 1
- 241001509504 Clostridium botulinum F Species 0.000 description 1
- 241000186227 Corynebacterium diphtheriae Species 0.000 description 1
- 241001487058 Corynebacterium efficiens YS-314 Species 0.000 description 1
- 241000186226 Corynebacterium glutamicum Species 0.000 description 1
- 241000671338 Corynebacterium glutamicum R Species 0.000 description 1
- 241001525611 Corynebacterium kroppenstedtii DSM 44385 Species 0.000 description 1
- 241000605765 Desulfovibrio salexigens Species 0.000 description 1
- 241000933091 Dinoroseobacter shibae DFL 12 = DSM 16493 Species 0.000 description 1
- 241000608038 Fibrobacter succinogenes subsp. succinogenes S85 Species 0.000 description 1
- 241000359186 Finegoldia magna ATCC 29328 Species 0.000 description 1
- 241000382842 Flavobacterium psychrophilum Species 0.000 description 1
- 108050008753 HNH endonucleases Proteins 0.000 description 1
- 102000000310 HNH endonucleases Human genes 0.000 description 1
- 241001453258 Helicobacter hepaticus Species 0.000 description 1
- 101000976622 Homo sapiens Zinc finger protein 42 homolog Proteins 0.000 description 1
- 241001063987 Kribbella flavida Species 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 241000917009 Lactobacillus rhamnosus GG Species 0.000 description 1
- 241001427851 Lactobacillus salivarius UCC118 Species 0.000 description 1
- 241001193656 Legionella pneumophila str. Paris Species 0.000 description 1
- 241000186805 Listeria innocua Species 0.000 description 1
- 241001378931 Methanococcus maripaludis C7 Species 0.000 description 1
- 241000825684 Mycobacterium abscessus ATCC 19977 Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 241000204022 Mycoplasma gallisepticum Species 0.000 description 1
- 241000107400 Mycoplasma mobile 163K Species 0.000 description 1
- 241001135743 Mycoplasma penetrans Species 0.000 description 1
- 241000051161 Mycoplasma synoviae 53 Species 0.000 description 1
- 241000156211 Neisseria meningitidis 053442 Species 0.000 description 1
- 241000529650 Neisseria meningitidis Z2491 Species 0.000 description 1
- 241000554781 Neisseria meningitidis alpha14 Species 0.000 description 1
- 241001648684 Nitrobacter hamburgensis X14 Species 0.000 description 1
- 101150085710 OCT4 gene Proteins 0.000 description 1
- 241000606856 Pasteurella multocida Species 0.000 description 1
- 241000549884 Persephonella marina EX-H1 Species 0.000 description 1
- 241000695265 Pseudoalteromonas atlantica T6c Species 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 241000647111 Rhodococcus erythropolis PR4 Species 0.000 description 1
- 241001459443 Rhodococcus jostii RHA1 Species 0.000 description 1
- 241001113889 Rhodococcus opacus B4 Species 0.000 description 1
- 241000190932 Rhodopseudomonas Species 0.000 description 1
- 241001303434 Rhodopseudomonas palustris BisB18 Species 0.000 description 1
- 241000134686 Rhodospirillum rubrum ATCC 11170 Species 0.000 description 1
- 241000516659 Roseiflexus Species 0.000 description 1
- 241000504328 Roseiflexus castenholzii DSM 13941 Species 0.000 description 1
- 241000933177 Shewanella pealeana ATCC 700345 Species 0.000 description 1
- 241001496704 Slackia heliotrinireducens DSM 20476 Species 0.000 description 1
- 241001478878 Streptobacillus Species 0.000 description 1
- 241001288016 Streptococcus gallolyticus Species 0.000 description 1
- 241001147754 Streptococcus gordonii str. Challis Species 0.000 description 1
- 241000672607 Streptococcus mutans NN2025 Species 0.000 description 1
- 241000103155 Streptococcus pyogenes MGAS10270 Species 0.000 description 1
- 241001520169 Streptococcus pyogenes MGAS315 Species 0.000 description 1
- 241001332083 Streptococcus pyogenes MGAS6180 Species 0.000 description 1
- 241000103156 Streptococcus pyogenes MGAS9429 Species 0.000 description 1
- 241001496716 Streptococcus pyogenes NZ131 Species 0.000 description 1
- 241001217892 Streptococcus thermophilus CNRZ1066 Species 0.000 description 1
- 241001633172 Streptococcus thermophilus LMD-9 Species 0.000 description 1
- 241000079831 Streptococcus thermophilus LMG 18311 Species 0.000 description 1
- 241000192593 Synechocystis sp. PCC 6803 Species 0.000 description 1
- 241001496699 Thermomonospora curvata DSM 43183 Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000847071 Verminephrobacter eiseniae EF01-2 Species 0.000 description 1
- 241000605941 Wolinella Species 0.000 description 1
- 241000883281 [Clostridium] cellulolyticum H10 Species 0.000 description 1
- 241001531188 [Eubacterium] rectale Species 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000037006 agalactosis Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 108020001778 catalytic domains Proteins 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000012350 deep sequencing Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 229940059406 lactobacillus rhamnosus gg Drugs 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940051027 pasteurella multocida Drugs 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 108010054624 red fluorescent protein Proteins 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361844844P | 2013-07-10 | 2013-07-10 | |
| US61/844,844 | 2013-07-10 | ||
| PCT/US2014/045700 WO2015006294A2 (en) | 2013-07-10 | 2014-07-08 | Orthogonal cas9 proteins for rna-guided gene regulation and editing |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019238875A Division JP7153992B2 (ja) | 2013-07-10 | 2019-12-27 | Ｒｎａ誘導性遺伝子制御および編集のための直交性ｃａｓ９タンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016523560A JP2016523560A (ja) | 2016-08-12 |
| JP2016523560A5 true JP2016523560A5 (enExample) | 2017-07-27 |
| JP6718813B2 JP6718813B2 (ja) | 2020-07-08 |
Family
ID=52280701
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016525414A Active JP6718813B2 (ja) | 2013-07-10 | 2014-07-08 | Ｒｎａ誘導性遺伝子制御および編集のための直交性ｃａｓ９タンパク質 |
| JP2019238875A Active JP7153992B2 (ja) | 2013-07-10 | 2019-12-27 | Ｒｎａ誘導性遺伝子制御および編集のための直交性ｃａｓ９タンパク質 |
| JP2022159833A Pending JP2022176275A (ja) | 2013-07-10 | 2022-10-03 | Ｒｎａ誘導性遺伝子制御および編集のための直交性ｃａｓ９タンパク質 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019238875A Active JP7153992B2 (ja) | 2013-07-10 | 2019-12-27 | Ｒｎａ誘導性遺伝子制御および編集のための直交性ｃａｓ９タンパク質 |
| JP2022159833A Pending JP2022176275A (ja) | 2013-07-10 | 2022-10-03 | Ｒｎａ誘導性遺伝子制御および編集のための直交性ｃａｓ９タンパク質 |
Country Status (12)
| Country | Link |
|---|---|
| US (5) | US10329587B2 (enExample) |
| EP (2) | EP3666892A1 (enExample) |
| JP (3) | JP6718813B2 (enExample) |
| KR (2) | KR102285485B1 (enExample) |
| CN (2) | CN105517579B (enExample) |
| AU (4) | AU2014287397B2 (enExample) |
| BR (1) | BR112016000571B1 (enExample) |
| CA (2) | CA3218040A1 (enExample) |
| IL (3) | IL282489B (enExample) |
| RU (3) | RU2748433C2 (enExample) |
| SG (3) | SG10201913015XA (enExample) |
| WO (1) | WO2015006294A2 (enExample) |
Families Citing this family (140)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR085533A1 (es) | 2011-03-23 | 2013-10-09 | Pioneer Hi Bred Int | Metodos de produccion de un locus de rasgos transgenicos complejo |
| WO2013066438A2 (en) | 2011-07-22 | 2013-05-10 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| ES2728782T3 (es) | 2012-05-25 | 2019-10-28 | Univ California | Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN |
| DK3363902T3 (da) | 2012-12-06 | 2020-01-02 | Sigma Aldrich Co Llc | Crispr-baseret genommodifikation og -regulering |
| IL308158A (en) | 2012-12-17 | 2023-12-01 | Harvard College | Rna-guided human genome engineering |
| DK3456831T3 (da) | 2013-04-16 | 2021-09-06 | Regeneron Pharma | Målrettet modifikation af rottegenom |
| US9163284B2 (en) | 2013-08-09 | 2015-10-20 | President And Fellows Of Harvard College | Methods for identifying a target site of a Cas9 nuclease |
| CN106133138A (zh) | 2013-08-22 | 2016-11-16 | 先锋国际良种公司 | 使用引导多核苷酸/cas内切核酸酶系统的基因组修饰及其使用方法 |
| US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
| US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
| US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
| US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
| ES2681622T3 (es) | 2013-09-18 | 2018-09-14 | Kymab Limited | Métodos, células y organismos |
| CN111218447B (zh) | 2013-11-07 | 2024-10-11 | 爱迪塔斯医药有限公司 | 使用统治型gRNA的CRISPR相关方法和组合物 |
| US11326209B2 (en) * | 2013-11-07 | 2022-05-10 | Massachusetts Institute Of Technology | Cell-based genomic recorded accumulative memory |
| MX388127B (es) | 2013-12-11 | 2025-03-19 | Regeneron Pharma | Metodos y composiciones para la modificacion dirigida de un genoma. |
| US20150166984A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting alpha-antitrypsin point mutations |
| US11028388B2 (en) | 2014-03-05 | 2021-06-08 | Editas Medicine, Inc. | CRISPR/Cas-related methods and compositions for treating Usher syndrome and retinitis pigmentosa |
| US9938521B2 (en) | 2014-03-10 | 2018-04-10 | Editas Medicine, Inc. | CRISPR/CAS-related methods and compositions for treating leber's congenital amaurosis 10 (LCA10) |
| US11339437B2 (en) | 2014-03-10 | 2022-05-24 | Editas Medicine, Inc. | Compositions and methods for treating CEP290-associated disease |
| US11141493B2 (en) | 2014-03-10 | 2021-10-12 | Editas Medicine, Inc. | Compositions and methods for treating CEP290-associated disease |
| EP3981876A1 (en) | 2014-03-26 | 2022-04-13 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating sickle cell disease |
| EP3540061A1 (en) | 2014-04-02 | 2019-09-18 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating primary open angle glaucoma |
| AU2015298571B2 (en) | 2014-07-30 | 2020-09-03 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
| BR112017003757A2 (pt) | 2014-09-12 | 2017-12-26 | Du Pont | ?plantas de milho, partes de planta de milho ou sementes de milho? |
| EP3204496A1 (en) | 2014-10-10 | 2017-08-16 | Editas Medicine, Inc. | Compositions and methods for promoting homology directed repair |
| GB201418965D0 (enExample) | 2014-10-24 | 2014-12-10 | Ospedale San Raffaele And Fond Telethon | |
| WO2016073990A2 (en) | 2014-11-07 | 2016-05-12 | Editas Medicine, Inc. | Methods for improving crispr/cas-mediated genome-editing |
| CA2969619A1 (en) | 2014-12-03 | 2016-06-09 | Agilent Technologies, Inc. | Guide rna with chemical modifications |
| WO2016094679A1 (en) | 2014-12-10 | 2016-06-16 | Regents Of The University Of Minnesota | Genetically modified cells, tissues, and organs for treating disease |
| BR112017017260A2 (pt) | 2015-03-27 | 2018-04-17 | Du Pont | construções de dna, vetor, célula, plantas, semente, método de expressão de rna e método de modificação de local alvo |
| CN107787367B (zh) | 2015-04-06 | 2021-10-26 | 里兰斯坦福初级大学理事会 | 用于crispr/cas介导的基因调控的化学修饰的引导rna |
| EP4019975A1 (en) | 2015-04-24 | 2022-06-29 | Editas Medicine, Inc. | Evaluation of cas9 molecule/guide rna molecule complexes |
| CA2986310A1 (en) | 2015-05-11 | 2016-11-17 | Editas Medicine, Inc. | Optimized crispr/cas9 systems and methods for gene editing in stem cells |
| MX2017014560A (es) * | 2015-05-15 | 2018-03-01 | Pioneer Hi Bred Int | Caracterizacion rapida de sistemas de endonucleasa cas, secuencias pam y elementos arn de guia. |
| SG10201914137YA (en) | 2015-06-01 | 2020-02-27 | Univ Temple | Methods and compositions for rna-guided treatment of hiv infection |
| US11911415B2 (en) | 2015-06-09 | 2024-02-27 | Editas Medicine, Inc. | CRISPR/Cas-related methods and compositions for improving transplantation |
| WO2016205745A2 (en) * | 2015-06-18 | 2016-12-22 | The Broad Institute Inc. | Cell sorting |
| EP4339287A3 (en) | 2015-07-31 | 2024-05-22 | Regents Of The University Of Minnesota | Modified cells and methods of therapy |
| CA2999500A1 (en) | 2015-09-24 | 2017-03-30 | Editas Medicine, Inc. | Use of exonucleases to improve crispr/cas-mediated genome editing |
| WO2017070632A2 (en) | 2015-10-23 | 2017-04-27 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
| WO2017074943A1 (en) * | 2015-10-27 | 2017-05-04 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of inducibly targeting chromatin effectors and compositions for use in the same |
| AU2016359629B2 (en) * | 2015-11-23 | 2023-03-09 | Ranjan BATRA | Tracking and manipulating cellular RNA via nuclear delivery of CRISPR/Cas9 |
| JP7012645B2 (ja) | 2016-01-11 | 2022-01-28 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | キメラタンパク質および免疫治療の方法 |
| WO2017123559A2 (en) | 2016-01-11 | 2017-07-20 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric proteins and methods of regulating gene expression |
| WO2017122096A1 (en) * | 2016-01-15 | 2017-07-20 | Astrazeneca Ab | Gene modification assays |
| WO2017165826A1 (en) | 2016-03-25 | 2017-09-28 | Editas Medicine, Inc. | Genome editing systems comprising repair-modulating enzyme molecules and methods of their use |
| EP3433364A1 (en) | 2016-03-25 | 2019-01-30 | Editas Medicine, Inc. | Systems and methods for treating alpha 1-antitrypsin (a1at) deficiency |
| WO2017180786A2 (en) * | 2016-04-12 | 2017-10-19 | Edward Perkins | Methods for creating synthetic chromosomes having gene regulatory systems and uses thereof |
| CN109328232A (zh) | 2016-04-12 | 2019-02-12 | 辛普洛德生物技术有限责任公司 | 用于产生表达生物合成通路的合成染色体的方法及其用途 |
| US11236313B2 (en) | 2016-04-13 | 2022-02-01 | Editas Medicine, Inc. | Cas9 fusion molecules, gene editing systems, and methods of use thereof |
| US10767175B2 (en) | 2016-06-08 | 2020-09-08 | Agilent Technologies, Inc. | High specificity genome editing using chemically modified guide RNAs |
| WO2017222834A1 (en) * | 2016-06-10 | 2017-12-28 | City Of Hope | Compositions and methods for mitochondrial genome editing |
| US11566263B2 (en) | 2016-08-02 | 2023-01-31 | Editas Medicine, Inc. | Compositions and methods for treating CEP290 associated disease |
| WO2018027078A1 (en) | 2016-08-03 | 2018-02-08 | President And Fellows Of Harard College | Adenosine nucleobase editors and uses thereof |
| AU2017308889B2 (en) | 2016-08-09 | 2023-11-09 | President And Fellows Of Harvard College | Programmable Cas9-recombinase fusion proteins and uses thereof |
| CN106282228A (zh) * | 2016-08-19 | 2017-01-04 | 苏州兰希亚生物科技有限公司 | 一种基因点突变修复的方法 |
| WO2018039438A1 (en) | 2016-08-24 | 2018-03-01 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| US20190225974A1 (en) | 2016-09-23 | 2019-07-25 | BASF Agricultural Solutions Seed US LLC | Targeted genome optimization in plants |
| KR20240007715A (ko) | 2016-10-14 | 2024-01-16 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵염기 에디터의 aav 전달 |
| EP4338799A3 (en) | 2016-10-18 | 2024-06-05 | Regents of the University of Minnesota | Tumor infiltrating lymphocytes and methods of therapy |
| WO2018083606A1 (en) | 2016-11-01 | 2018-05-11 | Novartis Ag | Methods and compositions for enhancing gene editing |
| EP3555297A1 (en) | 2016-12-19 | 2019-10-23 | Editas Medicine, Inc. | Assessing nuclease cleavage |
| WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
| WO2018129368A2 (en) | 2017-01-06 | 2018-07-12 | Editas Medicine, Inc. | Methods of assessing nuclease cleavage |
| WO2018140899A1 (en) * | 2017-01-28 | 2018-08-02 | Inari Agriculture, Inc. | Novel plant cells, plants, and seeds |
| TW201839136A (zh) | 2017-02-06 | 2018-11-01 | 瑞士商諾華公司 | 治療血色素異常症之組合物及方法 |
| US11866699B2 (en) | 2017-02-10 | 2024-01-09 | University Of Washington | Genome editing reagents and their use |
| US12440578B2 (en) | 2017-02-22 | 2025-10-14 | Io Biosciences, Inc. | Nucleic acid constructs comprising gene editing multi-sites and uses thereof |
| US10828330B2 (en) | 2017-02-22 | 2020-11-10 | IO Bioscience, Inc. | Nucleic acid constructs comprising gene editing multi-sites and uses thereof |
| WO2018165504A1 (en) | 2017-03-09 | 2018-09-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
| KR20190123328A (ko) | 2017-03-09 | 2019-10-31 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 암 백신 |
| CN110914310A (zh) | 2017-03-10 | 2020-03-24 | 哈佛大学的校长及成员们 | 胞嘧啶至鸟嘌呤碱基编辑器 |
| EP3596217A1 (en) | 2017-03-14 | 2020-01-22 | Editas Medicine, Inc. | Systems and methods for the treatment of hemoglobinopathies |
| GB2574561A (en) * | 2017-03-14 | 2019-12-11 | Univ California | Engineering CRISPR CAS9 immune stealth |
| IL306092A (en) | 2017-03-23 | 2023-11-01 | Harvard College | Nucleic base editors that include nucleic acid programmable DNA binding proteins |
| CN110892069B (zh) | 2017-03-30 | 2024-02-09 | 国立大学法人京都大学 | 基于基因组编辑的外显子跳跃诱导方法 |
| CN116732106A (zh) | 2017-04-20 | 2023-09-12 | E开创生物技术股份有限公司 | 产生基因修改的动物的方法 |
| US11499151B2 (en) | 2017-04-28 | 2022-11-15 | Editas Medicine, Inc. | Methods and systems for analyzing guide RNA molecules |
| WO2018208998A1 (en) | 2017-05-10 | 2018-11-15 | The Regents Of The University Of California | Directed editing of cellular rna via nuclear delivery of crispr/cas9 |
| EP3622070A2 (en) | 2017-05-10 | 2020-03-18 | Editas Medicine, Inc. | Crispr/rna-guided nuclease systems and methods |
| US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
| CN110997908A (zh) | 2017-06-09 | 2020-04-10 | 爱迪塔斯医药公司 | 工程化的cas9核酸酶 |
| US20200140896A1 (en) | 2017-06-30 | 2020-05-07 | Novartis Ag | Methods for the treatment of disease with gene editing systems |
| CN111511375A (zh) | 2017-06-30 | 2020-08-07 | 因提玛生物科学公司 | 用于基因治疗的腺相关病毒载体 |
| EP3652312A1 (en) | 2017-07-14 | 2020-05-20 | Editas Medicine, Inc. | Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites |
| EP3658573A1 (en) | 2017-07-28 | 2020-06-03 | President and Fellows of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace) |
| EP3676376B1 (en) | 2017-08-30 | 2025-01-15 | President and Fellows of Harvard College | High efficiency base editors comprising gam |
| KR102338449B1 (ko) | 2017-09-21 | 2021-12-10 | 더 브로드 인스티튜트, 인코퍼레이티드 | 표적화된 핵산 편집을 위한 시스템, 방법, 및 조성물 |
| US11603536B2 (en) | 2017-09-29 | 2023-03-14 | Inari Agriculture Technology, Inc. | Methods for efficient maize genome editing |
| CA3082251A1 (en) | 2017-10-16 | 2019-04-25 | The Broad Institute, Inc. | Uses of adenosine base editors |
| US11547614B2 (en) | 2017-10-31 | 2023-01-10 | The Broad Institute, Inc. | Methods and compositions for studying cell evolution |
| EP3704245A1 (en) | 2017-11-01 | 2020-09-09 | Novartis AG | Synthetic rnas and methods of use |
| BR112020009268A2 (pt) * | 2017-11-10 | 2020-11-17 | University Of Massachusetts | plataformas de distribuição de crispr direcionadas |
| US12406749B2 (en) | 2017-12-15 | 2025-09-02 | The Broad Institute, Inc. | Systems and methods for predicting repair outcomes in genetic engineering |
| CN111566121A (zh) | 2018-01-12 | 2020-08-21 | 巴斯夫欧洲公司 | 小麦7a染色体上决定每穗小穗数QTL的基因 |
| KR20200124702A (ko) | 2018-02-23 | 2020-11-03 | 파이어니어 하이 부렛드 인터내쇼날 인코포레이팃드 | 신규한 cas9 오르소로그 |
| IL277234B2 (en) | 2018-03-14 | 2026-03-01 | Editas Medicine Inc | Systems and methods for treating hemoglobin diseases |
| EP3592140A1 (en) | 2018-03-19 | 2020-01-15 | Regeneron Pharmaceuticals, Inc. | Transcription modulation in animals using crispr/cas systems |
| JP6614622B2 (ja) * | 2018-04-17 | 2019-12-04 | 国立大学法人名古屋大学 | 植物ゲノム編集方法 |
| AU2019255789B2 (en) | 2018-04-19 | 2025-11-20 | The Regents Of The University Of California | Compositions and methods for gene editing |
| WO2019226953A1 (en) | 2018-05-23 | 2019-11-28 | The Broad Institute, Inc. | Base editors and uses thereof |
| AU2019291918B2 (en) | 2018-06-29 | 2025-06-12 | Editas Medicine, Inc. | Synthetic guide molecules, compositions and methods relating thereto |
| EP3820495A4 (en) | 2018-07-09 | 2022-07-20 | The Broad Institute Inc. | RNA-PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES |
| GB201813011D0 (en) | 2018-08-10 | 2018-09-26 | Vib Vzw | Means and methods for drought tolerance in crops |
| EP3850088A4 (en) | 2018-09-07 | 2023-07-19 | Beam Therapeutics, Inc. | Compositions and methods for improving base editing |
| WO2020092453A1 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Nucleobase editors comprising geocas9 and uses thereof |
| CN113166744B (zh) | 2018-12-14 | 2025-02-07 | 先锋国际良种公司 | 用于基因组编辑的新颖crispr-cas系统 |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| JP7646552B2 (ja) | 2019-01-31 | 2025-03-17 | ビーム セラピューティクス インク． | 低減された非標的脱アミノ化を有する核酸塩基エディターおよび核酸塩基エディターの特徴づけのためのアッセイ |
| US12600971B2 (en) | 2019-02-13 | 2026-04-14 | Beam Therapeutics Inc. | Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence |
| EP3696189A1 (en) * | 2019-02-14 | 2020-08-19 | European Molecular Biology Laboratory | Means and methods for preparing engineered target proteins by genetic code expansion in a target protein selective manner |
| WO2020191241A1 (en) | 2019-03-19 | 2020-09-24 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
| US12637682B2 (en) | 2019-04-16 | 2026-05-26 | The Regents Of The University Of California | Protein translational control |
| WO2020214842A1 (en) | 2019-04-17 | 2020-10-22 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| CN118813654A (zh) | 2019-08-12 | 2024-10-22 | 生命编辑制药股份有限公司 | Rna指导的核酸酶及其活性片段及变体以及使用方法 |
| US12594301B2 (en) | 2019-09-27 | 2026-04-07 | Beam Therapeutics Inc. | Compositions and methods for treatment of liquid cancers |
| AU2020357816A1 (en) * | 2019-09-30 | 2022-04-14 | Sigma-Aldrich Co. Llc | Modulation of microbiota compositions using targeted nucleases |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| EP4085133A1 (en) * | 2019-12-30 | 2022-11-09 | Lifeedit Therapeutics, Inc. | Rna-guided nucleases and active fragments and variants thereof and methods of use |
| JP7525140B2 (ja) * | 2020-01-31 | 2024-07-30 | 国立大学法人京都大学 | タンパク質翻訳の制御システム |
| CA3177481A1 (en) | 2020-05-08 | 2021-11-11 | David R. Liu | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
| GB202007943D0 (en) * | 2020-05-27 | 2020-07-08 | Snipr Biome Aps | Products & methods |
| AU2021347359A1 (en) | 2020-09-25 | 2023-05-18 | Beam Therapeutics Inc. | Fratricide resistant modified immune cells and methods of using the same |
| RU2749307C1 (ru) * | 2020-10-30 | 2021-06-08 | Федеральное государственное бюджетное научное учреждение "Всероссийский научно-исследовательский институт сельскохозяйственной биотехнологии" (ФГБНУ ВНИИСБ) | Новая компактная нуклеаза CAS9 II типа из Anoxybacillus flavithermus |
| IL302830A (en) | 2020-11-13 | 2023-07-01 | Egenesis Inc | Cells, tissues, organs and animals with one or more genes that have been modified for improved survival and tolerance of a different-sex transplant |
| WO2022116139A1 (zh) * | 2020-12-04 | 2022-06-09 | 中国科学院脑科学与智能技术卓越创新中心 | 一种检测细胞内源性低丰度基因和lncRNA水平的方法 |
| AU2022216614B2 (en) | 2021-02-05 | 2026-03-05 | Christiana Care Gene Editing Institute, Inc. | Methods of and compositions for reducing gene expression and/or activity |
| WO2023039586A1 (en) | 2021-09-10 | 2023-03-16 | Agilent Technologies, Inc. | Guide rnas with chemical modification for prime editing |
| EP4426828A1 (en) | 2021-11-01 | 2024-09-11 | Tome Biosciences, Inc. | Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo |
| AU2022408167A1 (en) | 2021-12-08 | 2024-06-06 | Regeneron Pharmaceuticals, Inc. | Mutant myocilin disease model and uses thereof |
| US20250057980A1 (en) | 2021-12-22 | 2025-02-20 | Tome Biosciences, Inc. | Co-Delivery of a Gene Editor Construct and a Donor Template |
| WO2023205744A1 (en) | 2022-04-20 | 2023-10-26 | Tome Biosciences, Inc. | Programmable gene insertion compositions |
| WO2023225670A2 (en) | 2022-05-20 | 2023-11-23 | Tome Biosciences, Inc. | Ex vivo programmable gene insertion |
| WO2024020587A2 (en) | 2022-07-22 | 2024-01-25 | Tome Biosciences, Inc. | Pleiopluripotent stem cell programmable gene insertion |
| WO2024138194A1 (en) | 2022-12-22 | 2024-06-27 | Tome Biosciences, Inc. | Platforms, compositions, and methods for in vivo programmable gene insertion |
| WO2024234006A1 (en) | 2023-05-11 | 2024-11-14 | Tome Biosciences, Inc. | Systems, compositions, and methods for targeting liver sinusodial endothelial cells (lsecs) |
| WO2025050069A1 (en) | 2023-09-01 | 2025-03-06 | Tome Biosciences, Inc. | Programmable gene insertion using engineered integration enzymes |
| WO2025224107A1 (en) | 2024-04-22 | 2025-10-30 | Basecamp Research Ltd | Method and compositions for detecting off-target editing |
| WO2025224182A2 (en) | 2024-04-23 | 2025-10-30 | Basecamp Research Ltd | Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6933378B2 (en) * | 1997-05-30 | 2005-08-23 | Joseph Atabekov | Methods for coexpression of more than one gene in eukaryotic cells |
| US6203986B1 (en) | 1998-10-22 | 2001-03-20 | Robert H. Singer | Visualization of RNA in living cells |
| RU2467069C2 (ru) * | 2006-03-09 | 2012-11-20 | Зе Скрипс Ресеч Инститьют | Система экспрессии компонентов ортогональной трансляции в эубактериальной клетке-хозяине |
| US8481272B2 (en) * | 2006-08-04 | 2013-07-09 | Georgia State University Research Foundation, Inc. | Enzyme sensors, methods for preparing and using such sensors, and methods of detecting protease activity |
| MX2009009071A (es) | 2007-03-02 | 2009-09-24 | Danisco | Cultivos con resistencia mejorada a fagos. |
| US8546553B2 (en) | 2008-07-25 | 2013-10-01 | University Of Georgia Research Foundation, Inc. | Prokaryotic RNAi-like system and methods of use |
| US20100076057A1 (en) | 2008-09-23 | 2010-03-25 | Northwestern University | TARGET DNA INTERFERENCE WITH crRNA |
| WO2010054108A2 (en) | 2008-11-06 | 2010-05-14 | University Of Georgia Research Foundation, Inc. | Cas6 polypeptides and methods of use |
| US10087431B2 (en) | 2010-03-10 | 2018-10-02 | The Regents Of The University Of California | Methods of generating nucleic acid fragments |
| CA2798703A1 (en) | 2010-05-10 | 2011-11-17 | The Regents Of The University Of California | Endoribonuclease compositions and methods of use thereof |
| AU2011256838B2 (en) | 2010-05-17 | 2014-10-09 | Sangamo Therapeutics, Inc. | Novel DNA-binding proteins and uses thereof |
| US20140113376A1 (en) | 2011-06-01 | 2014-04-24 | Rotem Sorek | Compositions and methods for downregulating prokaryotic genes |
| WO2013066438A2 (en) * | 2011-07-22 | 2013-05-10 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| GB201122458D0 (en) * | 2011-12-30 | 2012-02-08 | Univ Wageningen | Modified cascade ribonucleoproteins and uses thereof |
| EP2836226B1 (en) | 2012-02-24 | 2017-06-28 | Fred Hutchinson Cancer Research Center | Compositions and methods for the treatment of hemoglobinopathies |
| CA2865011C (en) | 2012-02-29 | 2021-06-15 | Sangamo Biosciences, Inc. | Methods and compositions for treating huntington's disease |
| WO2013141680A1 (en) | 2012-03-20 | 2013-09-26 | Vilnius University | RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX |
| US9637739B2 (en) | 2012-03-20 | 2017-05-02 | Vilnius University | RNA-directed DNA cleavage by the Cas9-crRNA complex |
| ES2728782T3 (es) | 2012-05-25 | 2019-10-28 | Univ California | Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN |
| HK1207111A1 (en) | 2012-08-03 | 2016-01-22 | 加利福尼亚大学董事会 | Methods and compositions for controlling gene expression by rna processing |
| DK3363902T3 (da) * | 2012-12-06 | 2020-01-02 | Sigma Aldrich Co Llc | Crispr-baseret genommodifikation og -regulering |
| SG10201707569YA (en) * | 2012-12-12 | 2017-10-30 | Broad Inst Inc | Delivery, Engineering and Optimization of Systems, Methods and Compositions for Sequence Manipulation and Therapeutic Applications |
| CN105209621B (zh) * | 2012-12-12 | 2021-05-25 | 布罗德研究所有限公司 | 对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化 |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| IL308158A (en) * | 2012-12-17 | 2023-12-01 | Harvard College | Rna-guided human genome engineering |
| WO2014197748A2 (en) * | 2013-06-05 | 2014-12-11 | Duke University | Rna-guided gene editing and gene regulation |
-
2014
- 2014-07-08 CN CN201480048712.9A patent/CN105517579B/zh active Active
- 2014-07-08 AU AU2014287397A patent/AU2014287397B2/en active Active
- 2014-07-08 CN CN201910999512.6A patent/CN110819658B/zh active Active
- 2014-07-08 US US14/903,728 patent/US10329587B2/en active Active
- 2014-07-08 JP JP2016525414A patent/JP6718813B2/ja active Active
- 2014-07-08 CA CA3218040A patent/CA3218040A1/en active Pending
- 2014-07-08 EP EP19219620.2A patent/EP3666892A1/en active Pending
- 2014-07-08 RU RU2019132195A patent/RU2748433C2/ru active
- 2014-07-08 SG SG10201913015XA patent/SG10201913015XA/en unknown
- 2014-07-08 BR BR112016000571-6A patent/BR112016000571B1/pt active IP Right Grant
- 2014-07-08 KR KR1020167003074A patent/KR102285485B1/ko active Active
- 2014-07-08 EP EP14823626.8A patent/EP3019204B1/en active Active
- 2014-07-08 RU RU2016104161A patent/RU2704981C2/ru active
- 2014-07-08 IL IL282489A patent/IL282489B/en unknown
- 2014-07-08 SG SG10201800213VA patent/SG10201800213VA/en unknown
- 2014-07-08 CA CA2917639A patent/CA2917639C/en active Active
- 2014-07-08 KR KR1020217024118A patent/KR102481330B1/ko active Active
- 2014-07-08 SG SG11201600060VA patent/SG11201600060VA/en unknown
- 2014-07-08 WO PCT/US2014/045700 patent/WO2015006294A2/en not_active Ceased
-
2015
- 2015-03-31 US US14/674,895 patent/US9587252B2/en active Active
-
2016
- 2016-01-06 IL IL24347616A patent/IL243476B/en active IP Right Grant
-
2019
- 2019-05-14 US US16/411,793 patent/US11649469B2/en active Active
- 2019-10-29 IL IL270259A patent/IL270259B/en active IP Right Grant
- 2019-12-27 JP JP2019238875A patent/JP7153992B2/ja active Active
-
2020
- 2020-01-09 AU AU2020200163A patent/AU2020200163C1/en active Active
-
2021
- 2021-05-20 RU RU2021114286A patent/RU2771583C1/ru active
- 2021-11-25 AU AU2021273624A patent/AU2021273624C1/en active Active
-
2022
- 2022-10-03 JP JP2022159833A patent/JP2022176275A/ja active Pending
-
2023
- 2023-04-06 US US18/296,446 patent/US12577590B2/en active Active
-
2024
- 2024-10-28 AU AU2024227690A patent/AU2024227690B2/en active Active
-
2026
- 2026-02-12 US US19/537,643 patent/US20260159856A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2021273624C1 (en) | Orthogonal Cas9 proteins for RNA-guided gene regulation and editing | |
| IL272193A (en) | Genome engineering | |
| HK40031893A (en) | Orthogonal cas9 proteins for rna-guided gene regulation and editing | |
| HK1217907B (en) | Orthogonal cas9 proteins for rna-guided gene regulation and editing | |
| NZ754837B2 (en) | Orthogonal cas9 proteins for rna-guided gene regulation and editing | |
| NZ754836B2 (en) | Orthogonal cas9 proteins for rna-guided gene regulation and editing | |
| NZ716605B2 (en) | Orthogonal cas9 proteins for rna-guided gene regulation and editing |